EDAP TMS S.A. interim filing shows revenue growth alongside widening losses on both the three-month and six-month windows

Bottom line

The headline reading of this filing, drawn from the condensed consolidated statements presented inside the quarterly report, is that EDAP TMS S.A. finished the three-month reporting period and the six-month year-to-date window in a loss position on both the top line and the bottom line, while revenue itself moved upward against the comparable prior-year windows. The diluted earnings per share figure for the current three-month reporting period was a loss, and the same metric for the prior-year comparative three-month reporting period was also a loss; the authorized direction is decrease, with the transition reading loss to loss. The diluted earnings per share for the current six-month year-to-date period was a loss, as was the prior-year six-month comparative; again the authorized direction is decrease, with the transition loss to loss. Net income attributable to parent followed the same pattern: a loss for the current three-month reporting period, a loss for the prior-year three-month comparative, direction decrease, transition loss to loss; and a loss for the current six-month year-to-date period alongside a loss for the prior-year six-month comparative, direction decrease, transition loss to loss. Operating income tracked identically, with the current three-month reporting period showing a loss against a loss in the prior-year comparative three-month window, direction decrease, transition loss to loss, and the current six-month year-to-date period showing a loss against a loss in the prior-year six-month comparative, direction decrease, transition loss to loss. Revenue, by contrast, registered the only positive directional move in this section, rising in the current three-month reporting period against the prior-year comparative three-month window, and rising again in the current six-month year-to-date period against the prior-year comparative six-month window, both with positive values on each side.

The reporting entity itself is EDAP TMS S.A., identified as a smaller reporting company preparing unaudited condensed consolidated financial statements in accordance with U.S. GAAP for interim financial information. The statements cover the three months and six months ended June of the current and prior years, presented in thousands of U.S. dollars, with operating results for the six months ended June described as not necessarily indicative of the full fiscal year ending December of the current year. The forward-looking statements passage inside the filing flags a broad list of risk factors relevant to the reported numbers, including regulatory and reimbursement uncertainty for HIFU technology, the intended discontinuation of the ESWL and Distribution operating segments, foreign exchange exposure between the euro and the U.S. dollar and between the euro and the Japanese yen, and the cyclicality of medical device demand, among others.

The filing evidence does not attribute the deterioration in earnings to any single cause. The filing evidence does not attribute this change to any single cause.

Financial performance

This section reviews how the interim period compared with the prior year on both the three-month and six-month windows, the accounting backdrop that frames those results, and the baseline readers should keep in mind when interpreting the change.

Reported financial results

For the three-month reporting period, Revenues were $13,203,000 USD, higher than the prior-year comparative Revenues of $9,509,000 USD. Operating Income (Loss) for the three-month reporting period was a loss of -$8,033,000 USD, a deeper loss than the prior-year comparative Operating Income (Loss) of -$6,623,000 USD. Net Income (Loss) Attributable to Parent for the three-month reporting period was a loss of -$14,487,000 USD, deeper than the prior-year comparative Net Income (Loss) Attributable to Parent of -$6,406,000 USD. Earnings Per Share, Diluted for the three-month reporting period was a loss of -$0.39 per diluted share USD/SHARES, a deeper loss than the prior-year comparative Earnings Per Share, Diluted of -$0.17 per diluted share USD/SHARES.

For the six-month year-to-date period, Revenues were $24,796,000 USD, higher than the prior-year comparative Revenues of $16,009,000 USD. Operating Income (Loss) for the six-month year-to-date period was a loss of -$16,057,000 USD, a deeper loss than the prior-year comparative Operating Income (Loss) of -$13,368,000 USD. Net Income (Loss) Attributable to Parent for the six-month year-to-date period was a loss of -$23,570,000 USD, deeper than the prior-year comparative Net Income (Loss) Attributable to Parent of -$13,850,000 USD. Earnings Per Share, Diluted for the six-month year-to-date period was a loss of -$0.63 per diluted share USD/SHARES, a deeper loss than the prior-year comparative Earnings Per Share, Diluted of -$0.37 per diluted share USD/SHARES.

Management commentary and accounting context

Management describes the filing as an interim report prepared in accordance with U.S. generally accepted accounting principles for interim financial information, and the Company qualifies as a smaller reporting company under SEC rules. The filing evidence does not attribute this change to any single cause.

A significant accounting context is the discontinued-operations treatment described in Note 1. During the second quarter of the three months ended June 30, 2025, the ESWL and Distribution segments met the criteria to be classified as held for sale under ASC presentation of financial statements on discontinued operations and ASC on property, plant, and equipment, and management determined that the planned exit represents a strategic shift that will have a major effect on the Company's operations and financial results. The results of the ESWL and Distribution segments are reported as discontinued operations in the condensed consolidated statements of operations for all periods presented. Disposal groups were measured at the lower of their carrying amount and fair value less costs to sell, and no impairment loss was recognized upon classification as held for sale.

Note 1 also describes the Summary of Significant Accounting Policies, confirming that there have been no changes in significant accounting policies other than the discontinued-operations disclosure, and that disposal groups classified as held for sale are measured at the lower of carrying amount and fair value less costs to sell, with depreciation and amortization ceasing upon classification.

Counter-evidence and unknowns

The filing evidence contains no peer or industry comparison.

Forward-looking statements speak only as of the date on which they are made, and the Company refers readers to the Risk Factors section of the prior Annual Report on Form referenced in the filing.

Operating drivers and segments

- Revenue at EDAP TMS SA for the three-month reporting period the three months ended June 30, 2026 came in at $13,203,000, higher than the prior-year comparative of $9,509,000 for the three months ended June 30, 2025, per the Condensed Consolidated Statements of Operations. - Revenue for the six-month year-to-date period the six months ended June 30, 2026 was $24,796,000, also higher than the prior-year comparative of $16,009,000 for the six months ended June 30, 2025. - Operating Income (Loss) was a loss on both windows, and the loss widened year over year: -$8,033,000 for the three months ended June 30, 2026 versus -$6,623,000 for the three months ended June 30, 2025, and -$16,057,000 for the six months ended June 30, 2026 versus -$13,368,000 for the six months ended June 30, 2025. Revenues moved up while operating loss moved in the opposite direction, which the reported comparison records as a decrease in operating income (loss to loss) on both windows. - The catalog for this filing does not include a segment-level revenue or operating-income disaggregation by HIFU versus ESWL versus the Distribution division, so each segment's contribution to revenue or to operating loss cannot be isolated from the disclosed figures. - The catalog also does not list cost-of-revenue, gross-profit, or operating-expense line items for this section, which limits how narrowly the operating-margin bridge from revenue growth to operating-loss widening can be described.

- Management frames forward-looking commentary around High Intensity Focused Ultrasound ("HIFU"), citing "the success of our HIFU technology," "the uncertainty of market acceptance for our HIFU devices," and "the market potential for our HIFU devices," positioning HIFU as the strategic growth driver. - Management also flags the ESWL and Distribution segment wind-down as an explicit strategic action, noting that "the discontinuation may take longer or cost more than expected, may result in disputes with customers, distributors, employees or other counterparties, and may not produce the strategic benefits anticipated." - Beyond those two themes, the forward-looking section is a standard risk-factor recitation covering regulatory review, reimbursement status, competition, currency exposure, capital availability, production-site concentration, and cybersecurity.

Independent analysis versus management claims: - The HIFU-centric narrative is consistent with revenue growing on both windows, but the filing evidence does not isolate HIFU versus the legacy segments, so the strength of that mix shift cannot be verified from the disclosed figures. - The widening operating loss alongside higher revenue points to operating-cost growth outpacing top-line growth, but the catalog does not list the cost lines needed to quantify that gap, so The filing evidence does not attribute this change to any single cause. applies to the operating-margin deterioration. - The discontinued-operations accounting context (see Note 1 and Note 18) signals that some prior-period income-statement activity is reclassified, which can independently move both reported revenue and reported operating loss; the filing evidence does not present the continuing-operations versus discontinued-operations split that would let us separate that effect from underlying business performance. - The filing, identified by 10-Q and period-ended-2026-06-30 under accession 0001104659-26-097063, presents no peer or industry benchmark, so The filing evidence contains no peer or industry comparison. applies when comparing the operating-loss profile against sector peers.

Cash flow and capital

- The interim filing for EDAP TMS SA under 10-Q for period-ended-2026-06-30 (accession 0001104659-26-097063, CIK 0001041934, ticker FOCL) frames the cash flow statement as a continuing-operations view, with prior-period amounts reclassified to match the current presentation for discontinued operations (see Note 18). That reclassification is a presentation choice, not a change in underlying economic activity.

- On the operating side, Net Cash Provided by (Used in) Operating Activities was -$6,663,000 for the six months ended June 30, 2026 and -$10,047,000 for the six months ended June 30, 2025. The authorized direction is increase, and the reported current figure is negative while the prior comparative is also negative — meaning the cash burn moderated year over year without crossing into positive territory. The filing itself does not attribute the moderation to any single cause, so any further read on drivers is The filing evidence does not attribute this change to any single cause..

- On the investing side, Net Cash Provided by (Used in) Investing Activities was -$2,017,000 for the current period and -$2,917,000 for the comparative period; both are negative, and the authorized direction is increase. The continuation of negative investing cash flow alongside a moderating but still negative operating result points to a profile in which the business is still consuming cash rather than self-funding.

- On the financing side, Net Cash Provided by (Used in) Financing Activities was $10,402,000 for the current half-year and -$1,198,000 for the comparative, with the authorized direction of increase moving the line from a negative comparative to a positive current value — i.e., a flip from cash outflow to cash inflow in financing during the period.

- The liquid asset position at the balance sheet date of June 30, 2026 shows Cash and Cash Equivalents, at Carrying Value, of $21,542,000. This is the balance that funds the negative operating and investing readings above.

- The credit profile on the same balance sheet date shows Long-term Debt, Excluding Current Maturities, of $37,197,000. This item relates to the EIB Credit Facility and Warrants described in the debt footnote, which remains the Company's primary long-dated financing arrangement supporting the Robotics HIFU research and development program.

- Working-capital receivables at the balance sheet date were reported on three related bases: Accounts Receivable, before Allowance for Credit Loss, of $11,597,000; Accounts Receivable, after Allowance for Credit Loss, of $11,062,000; and the Current portion recorded at $10,060,000. The gross-versus-net pair reflects an allowance for credit loss that the filing does not quantify in narrative form; the linked Lizely Finance Earnings Analysis on interim filings illustrates how readers commonly compare these three readings to gauge collection risk across reporting cycles.

- Capital allocation stance across the period is best described as defensive liquidity management rather than growth investment: operating cash flow remained negative but improved, investing cash flow remained negative, and financing cash flow moved from a negative comparative into a positive current reading, with $21,542,000 of cash on hand and $37,197,000 of long-term debt outstanding against Note 18's reclassified continuing-operations balance sheet.

Peer and historical context

- The filing evidence for this interim report, filed by EDAP TMS SA as 10-Q for period-ended-2026-06-30 under accession 0001104659-26-097063, contains only the issuer's own prior-period comparatives. There is no peer roster, no industry index, no competitor multiple, and no segment-of-cohort benchmark in the cited materials. The filing evidence contains no peer or industry comparison.

As a result, the only historical comparison available is internal: the same issuer's three-month and six-month year-to-date reporting periods set against the prior-year counterparts. - On that internal yardstick, the headline P&L shows a mixed pattern. Revenues moved in opposite directions on the two windows: for the three-month period, revenues were higher than the prior-year quarter, while the six-month year-to-date picture was the reverse, with revenues lower than the prior-year half-year period.

The earnings lines, however, deepened rather than reversed. Operating income (loss) was a loss on both periods and worsened on each: it was lower than the prior-year quarter and lower than the prior-year half-year. Net income (loss) attributable to parent followed the same contour — a loss on both windows, and lower than the prior-year three-month and six-month results.

The filing evidence does not attribute this change to any single cause. - The cash-flow side offers a different reading. Net cash provided by (used in) operating activities was negative in both six-month periods, but the current outflow was smaller than the prior-year outflow — the only authorized narrowing of an outflow in the catalog.

Net cash used in investing activities also narrowed its outflow year over year, while net cash provided by financing activities flipped from a use of cash in the prior year to a source of cash in the current half-year, consistent with the EIB Credit Facility and Warrants arrangement described in the cited note. - The accounting-pronouncements and goodwill notes reinforce the historical frame rather than the peer frame. Goodwill was tested using a discounted cash flow approach and was not impaired as of the balance sheet date, and management states that no recently issued accounting standards are expected to have a material impact on results, financial condition, or cash flows.

The discontinued-operations note referenced in the cited note means the year-over-year comparisons are presented on a continuing-operations basis, which itself can move the apparent trajectory even when the underlying business is stable. The filing evidence does not attribute this change to any single cause. - Readers looking for relative valuation or cohort context should treat this section as a two-period self-comparison only, and note that the worsening of bottom-line losses alongside a narrower operating cash outflow is the principal tension the filing displays.

For perspective on how a different medical-device name characterizes its own interim transition, the prior Lizely Finance analysis on UFP Technologies covers a profit-to-profit case that contrasts with the loss-to-loss profile here.

Scenario analysis

In the central case, EDAP TMS SA (FOCL, CIK 0001041934) carries the pattern visible in the 10-Q filing for period-ended-2026-06-30, accession 0001104659-26-097063, into the back half of the year without dramatic shifts. Reported facts show Revenues rising on both windows versus the prior-year comparative: $13,203,000 for the three months ended June 30, 2026 is higher than $9,509,000 for the three months ended June 30, 2025, and $24,796,000 for the six months ended June 30, 2026 is higher than $16,009,000 for the six months ended June 30, 2025. The authorized transition in both windows is a loss widening on the bottom line: Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 is a larger loss than -$13,850,000 for the six months ended June 30, 2025, and for the three months ended June 30, 2026 it is a larger loss than -$6,406,000 for the three months ended June 30, 2025. Operating Income (Loss) follows the same direction, sitting deeper in loss territory versus each comparative period. Management describes an exchange-rate-driven decrease in the allowance for slow-moving inventory and a still-unimpaired goodwill position, with the EIB Finance Contract and its freestanding Warrants classified under the cited liability framework. In this base reading, revenue keeps climbing, the loss deepens on a reported basis, and the warrant-related liability remains an ongoing fair-value swing factor. The filing evidence does not attribute this change to any single cause.

The constructive case leans on revenue continuing its year-over-year climb while the loss stops widening. Revenues at $13,203,000 and $24,796,000 remain above the comparative periods $9,509,000 and $16,009,000. The constructive case leans on Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 and the three months ended June 30, 2026 staying at a loss rather than moving to a deeper loss versus -$13,850,000 and -$6,406,000. Operating Income (Loss) on both windows narrows the gap toward break-even without crossing into profit, holding its authorized loss-to-loss shape. Management cites no goodwill impairment and reports a working Finance Contract with the EIB that continues to fund the Robotics HIFU program; in this case the warrant remeasurement does not push the loss wider. In the constructive case the EIB put-option cap referenced in the cited note is never approached and the warrant fair-value swings settle. The filing evidence contains no peer or industry comparison.

The cautious case leans on the loss extending while the loss stops widening at the same pace. Revenues at $13,203,000 and $24,796,000 stay positive but the year-over-year spread versus $9,509,000 and $16,009,000 thins. The cautious case leans on Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 and the three months ended June 30, 2026 moving deeper into loss versus -$13,850,000 and -$6,406,000, with Operating Income (Loss) widening on both windows in tandem. Management flags ongoing exchange-rate effects on the inventory allowance and a still-active EIB warrant program with a put-option cap referenced in the cited note; in this case the warrant remeasurement pulls the loss wider and the put cap is approached. The filing evidence does not attribute this change to any single cause.

For a contrasting read on a different interim filing where the top line climbed alongside the bottom line, see REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing.

Risks and what to watch

Reported facts - EDAP TMS SA filed an interim report under 10-Q for period-ended-2026-06-30, identified by 0001041934 and 0001104659-26-097063, with its shares trading under FOCL. - For the three-month reporting period the three months ended June 30, 2026, Revenues were $13,203,000 USD, higher than the prior-year comparative $9,509,000 USD for the three months ended June 30, 2025. - For the six-month year-to-date period the six months ended June 30, 2026, Revenues were $24,796,000 USD, higher than the prior-year comparative $16,009,000 USD for the six months ended June 30, 2025. - Net Income (Loss) Attributable to Parent was a loss in all four windows: -$14,487,000 USD for the three months ended June 30, 2026, -$6,406,000 USD for the three months ended June 30, 2025, -$23,570,000 USD for the six months ended June 30, 2026, and -$13,850,000 USD for the six months ended June 30, 2025. The half-year and quarter losses deepened versus their respective prior-year comparatives, while revenue on both windows grew.

Management explanations - Management describes the Tranche A and B borrowings together with the Tranche A and B Warrants as freestanding financial instruments under the cited ASC framework, allocating inception proceeds between the Warrants at initial fair value and a debt residual, with subsequent fair-value remeasurement of the Warrants through earnings and amortized-cost treatment of the debt. - Management notes a put option allowing EIB to require EDAP TMS SA to repurchase the Warrants in cash at fair market value, capped at (omitted) million, with any unexercised warrants remaining exercisable; such puttable warrants and similar instruments on redeemable shares are stated to require liability classification. - Management states the Company does not have a funded benefit plan and presents a reconciliation of pension cost components for the six months referenced in the cited note.

Analyst inference - The widening net loss on rising revenue suggests operating expenses, fair-value movements on the warrant liability, or financing costs are growing faster than the top line on both windows. - The disclosed put option held by EIB introduces a contingent cash outflow capped at the cited note amount, which is a balance-sheet liability item the market will track.

Counter-evidence - The headline revenue acceleration to $13,203,000 USD from $9,509,000 USD, and to $24,796,000 USD from $16,009,000 USD, cuts against a simple demand-collapse narrative and argues that commercial momentum is intact even as profitability deteriorated. - The pivot from negative to positive Net Cash Provided by (Used in) Financing Activities, alongside still-negative but changing Net Cash Provided by (Used in) Operating Activities and Net Cash Provided by (Used in) Investing Activities over the half-year window, indicates liquidity was actively managed rather than passively eroded.

Unknowns - The filing evidence does not break out revenue by geography, device line, or service line, so segment momentum cannot be judged; The filing evidence does not disclose segment-level detail for this dimension.. - The filing evidence does not benchmark EDAP TMS SA against sector peers or industry indices for the reporting windows; The filing evidence contains no peer or industry comparison.. - The filing evidence does not attribute this change to any single cause.. - Disclosure controls and procedures, legal proceedings, and risk-factor updates appear under Item 4, Item 1, and Item 1A, while other-information items and exhibits are filed under Item 2, Item 3, Item 5, and Item 6, and pension and discontinued-operations detail sits in the cited note and Note 1 alongside Note 18.

Metrics to watch next period - Whether revenue growth holds on both the quarter and half-year windows while the net loss narrows back toward the prior-year baseline. - The fair-value remeasurement of the EIB Warrants and any movement in the put-option cap cited in the relevant note, which can swing earnings non-operationally. - Net Cash Provided by (Used in) Operating Activities, given the half-year shift away from the prior-year usage level, and the trajectory of Investing and Financing flows alongside it. - Earnings Per Share, Diluted, which moved lower on both the quarter and half-year windows even as revenue rose. - Updates to risk factors and legal proceedings under Item 1 and Item 1A for any incremental disclosure that reframes the loss narrative.